NCT03558945

Clinical Trial on Personalized Neoantigen Vaccine for Pancreatic Tumor

Status unknown Phase 1 Last updated 24 April 2023

What this trial tests

Phase 1 trial testing Personalized neoantigen vaccine in Pancreatic Tumor in 30 participants. Status unknown.

Timeline

12 July 2018

Primary endpoint
30 November 2023

30 December 2023

Quick facts

Lead sponsor	Anda Biopharmaceutical Development (Shenzhen) Co., Ltd.
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	12 July 2018
Primary completion	30 November 2023
Estimated completion	30 December 2023
Sites	1 location across China

Drugs / interventions tested

• Personalized neoantigen vaccine — full drug profile →

Conditions studied

• Pancreatic Tumor — all drugs for Pancreatic Tumor →

Sponsor

Anda Biopharmaceutical Development (Shenzhen) Co., Ltd. — full company profile →

Who can join

Adults 20 to 75, any sex, with Pancreatic Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial is to evaluate the safety and impact on prognosis of personalized neoantigen peptide-based vaccines, which are based on next-generation sequencing and major histocompatibility complex affinity prediction algorithm, in patients with pancreatic ductal adenocarcinoma. The hypothesis of this study is that personalized neoantigen vaccines will be safe and can systemically elicit measurable neoantigen-specific immunologic responses in patients. Participants will receive complete macroscopic resection of primary tumor, standard adjuvant chemotherapy and subsequently personalized neoantigen vaccines.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Neoantigens: promising targets for cancer therapy.
   Xie N, Shen G, Gao W, Huang Z, et al · · 2023 · cited 713× · PMID 36604431 · DOI 10.1038/s41392-022-01270-x
2. Tumor neoantigens: from basic research to clinical applications.
   Jiang T, Shi T, Zhang H, Hu J, et al · · 2019 · cited 276× · PMID 31492199 · DOI 10.1186/s13045-019-0787-5
3. Beyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines.
   Stephens AJ, Burgess-Brown NA, Jiang S. · · 2021 · cited 112× · PMID 34276688 · DOI 10.3389/fimmu.2021.696791
4. Selecting Target Antigens for Cancer Vaccine Development.
   Buonaguro L, Tagliamonte M. · · 2020 · cited 97× · PMID 33080888 · DOI 10.3390/vaccines8040615
5. Pancreatic Cancer and Immunotherapy: A Clinical Overview.
   Timmer FEF, Geboers B, Nieuwenhuizen S, Dijkstra M, et al · · 2021 · cited 92× · PMID 34439292 · DOI 10.3390/cancers13164138
6. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.
   Chen X, Yang J, Wang L, Liu B. · · 2020 · cited 69× · PMID 32483434 · DOI 10.7150/thno.38742
7. Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine.
   Huang X, Zhang G, Tang TY, Gao X, et al · · 2022 · cited 61× · PMID 36224645 · DOI 10.1186/s40779-022-00416-w
8. Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials.
   Sobhani N, Scaggiante B, Morris R, Chai D, et al · · 2022 · cited 57× · PMID 35759856 · DOI 10.1016/j.ctrv.2022.102429